Alvotech (ALVO)
| Market Cap | 2.80B |
| Revenue (ttm) | 587.89M |
| Net Income (ttm) | 96.55M |
| Shares Out | 303.47M |
| EPS (ttm) | 0.34 |
| PE Ratio | 26.58 |
| Forward PE | 26.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,462 |
| Open | 8.90 |
| Previous Close | 9.01 |
| Day's Range | 8.73 - 9.27 |
| 52-Week Range | 7.35 - 13.79 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 18.00 (+94.91%) |
| Earnings Date | Aug 14, 2025 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]
Financial Performance
In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ALVO stock is "Buy" and the 12-month stock price forecast is $18.0.
News
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completio...
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completio...
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs...
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
REYKJAVIK, Iceland, June 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA , AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, ...
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Bi...
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...
Alvotech Annual General Meeting to be held June 25, 2025
The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy o...
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition ...
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liqu...
Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today
Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offe...
Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm
Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offe...
Alvotech (ALVO) Q1 2025 Earnings Call Transcript
Alvotech (NASDAQ:ALVO) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Benedikt Stefansson - VP, Investor Relations and Global Communications Robert Wessman - Founder, Ch...
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and ...
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pat...
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
REYKJAVIK, Iceland, May 7, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, to...
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticip...
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results ...
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, an...
Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)
Alvotech's stock has dropped significantly due to potential tariffs and ongoing profitability challenges, despite strong revenue growth and a promising biosimilar pipeline. The company's reliance on I...
This Is a Test From GlobeNewswire
This is a test from GlobeNewswire. Readers are advised to disregard.
Alvotech (ALVO) Q4 2024 Earnings Call Transcript
Alvotech (NASDAQ:ALVO) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph M...